Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 5.50 GBp
Change Today +0.125 / 2.33%
Volume 480.5K
RENE On Other Exchanges
As of 8:34 AM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Michael E. Hunt BSc, ACA

Chief Financial Officer and Executive Director, ReNeuron Group plc
AgeTotal Calculated CompensationThis person is connected to 20 board members in 1 different organizations across 1 different industries.

See Board Relationships
52284,000 GBP
As of Fiscal Year 2014


Mr. Michael E. Hunt, BSc, ACA has been the Chief Financial Officer at ReNeuron Group plc since September 8, 2014 and served as its Chief Executive Officer since July 2005 until September 8, 2014. Mr. Hunt served as Chief Financial Officer of ReNeuron Group plc. He served as the Chief Operating Officer of ReNeuron in September 2003 in addition to his duties as Finance Director. He served as Sercretary of ReNeuron Group plc. He spent six years at Biocompatibles International ...

Read Full Background

Corporate Headquarters*

10 Nugent Road
Guildford, Surrey GU2 7AF

United Kingdom

Phone: 44 14 8330 2560
Fax: 44 14 8353 4864

Board Members Memberships*

Chief Financial Officer and Executive Director


Unknown/Other Education
University College London

Other Affiliations*

Annual Compensation*

Salary200,000 GBP
Bonus62,000 GBP
Total Annual Compensation262,000 GBP

Stock Options*

All Other Compensation22,000 GBP
Exercisable Options12,720,070
Exercisable Options Value111,020 GBP
Unexercisable Options10,056,818
Unexercisable Options Value211,193 GBP
Total Value of Options322,213 GBP
Total Number of Options22,776,888

Total Compensation*

Total Annual Cash Compensation284,000 GBP
Total Short Term Compensation262,000 GBP
Other Long Term Compensation22,000 GBP
Total Calculated Compensation284,000 GBP
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RENE:LN 5.50 GBp +0.125


Michael D. West Ph.D.Chief Executive Officer, President and Director
BioTime, Inc.
Martin M. McGlynn Chief Executive Officer, Director, Member of Strategic Transactions Committee, Chief Executive Officer of Stemcells California Inc and President of Stemcells California Inc
StemCells Inc.
Paul K. Wotton Ph.D.Chief Executive Officer, President and Director
Ocata Therapeutics, Inc.
I. Richard Garr J.D.Co-Founder, Chief Executive Officer, President, General Counsel and Director
Neuralstem, Inc.
Andrey Semechkin Ph.D.Co-Chairman and Chief Executive Officer
International Stem Cell Corporation
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RENEURON GROUP PLC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at